Remo CRO


Janssen Announces U.S. FDA Breakthrough Therapy Designation for Erdafitinib in the Treatment of Metastatic Urothelial Cancer

03.20 2018.

RARITAN, NJ, March 15, 2018 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for erdafitinib in the treatment of… Details

AbbVie Announces Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids

03.20 2018.

NORTH CHICAGO, Ill., March 13, 2018 /PRNewswire/ — AbbVie (NYSE:ABBV), a global research and development-based biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), announced that the Phase 3 ELARIS UF-II study… Details

Lack of Clear Career Paths Chasing Employees Out the Door

03.16 2018.

A perceived lack of professional advancement and career development opportunities are the two biggest factors driving clinical trial professionals to seek employment elsewhere. That’s one of the key takeaways from a new survey by SCORR Marketing and Applied Clinical Trials. With just over 40% of respondents reporting they were currently looking for a new job, […] Details

Savara Initiates Phase 2a Clinical Study of Molgradex for the Treatment of NTM Lung Infection

03.15 2018.

AUSTIN, TX — (Marketwired) — 03/13/18 — Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, announced today the initiation of a Phase 2a clinical study, OPTIMA, evaluating its lead product candidate Molgradex, an inhaled formulation of… Details

Duke Attracts and Retains Top Candidates with Competency-Based Job Descriptions

03.15 2018.

Duke University Medical Center has organized some 180 formerly sprawling and sometimes vague job descriptions and honed them down to a dozen, based on professional competencies and clearly stated expectations. All told, Duke mapped more than 700 people. “I think we owe it to our patients to be very transparent about who’s doing what, how […] Details

Santhera Reports Outcome of Exploratory Trial with Idebenone in PPMS Conducted at the NIH

03.14 2018.

Pratteln, Switzerland, March 5, 2018 – Santhera Pharmaceuticals (SIX: SANN) announces that the exploratory Phase I/II clinical trial in primary progressive multiple sclerosis (PPMS) conducted as an investigator-initiated trial at the National… Details